194228-60-9

Usage

Heterocyclic organic compound

It contains both carbon and nitrogen atoms in its ring structure, making it a heterocyclic compound.

Chlorine and iodine atoms

The compound has three chlorine atoms at the 2nd, 6th, and 7th positions, and one iodine atom at the 3rd position.

Unique structure and properties

The presence of both chlorine and iodine atoms in the imidazo[1,2-a]pyridine ring gives 2,6,7-TRICHLORO-3-IODOIMIDAZO[1,2-A]PYRIDINE its unique structure and properties.

Potential applications in pharmaceuticals and agrochemicals

Due to its unique structure and properties, 2,6,7-TRICHLORO-3-IODOIMIDAZO[1,2-A]PYRIDINE can be used in the development of new drugs and agrochemicals.

Synthesis of biologically active compounds

2,6,7-trichloro-3-iodoimidazo[1,2-a]pyridine can be used as a building block in the synthesis of various biologically active compounds.

Intermediate in chemical production

2,6,7-TRICHLORO-3-IODOIMIDAZO[1,2-A]PYRIDINE can also serve as an intermediate in the production of other chemicals, further expanding its potential applications.

Handling precautions

It is important to handle 2,6,7-trichloro-3-iodoimidazo[1,2-a]pyridine with care, as it may pose risks to health and safety if not properly managed.

Upstream product

• 131773-47-2 2,6,7-Trichloroimidazo[1,2-a]pyridine 

Relevant academic research and scientific papers

Synthesis and antiviral activity of novel erythrofuranosyl imidazo[1,2-α]pyridine C-nucleosides constructed via palladium coupling of iodoimidazo[1,2-α]pyridines and dihydrofuran

2,5,6-Trichloro-1-(β-D-ribofuranosyl)benzimidazole (TCRB) and certain analogues have shown significant activity against human cytomegalovirus. The metabolic instability of the glycosidic linkage in TCRB prompted us to synthesize the structurally similar imidazo[1,2-α]pyridine erythrofuranosyl C-nucleosides. As an approach to the synthesis of polychlorinated imidazo-[1,2-α]pyridine C-3-erythrofuranosides, a palladium-based methodology for coupling 2,3-dihydrofuran with chlorinated 3-iodoimidazo[1,2-α]pyridines was developed and optimized to give 80-90% yields of 2,6-dichloro- and 2,6,7-trichloro-3-(2,3-dideoxy-2,3-didehydro-D/L-erythrofuranosyl)- imidazo[1,2-α]pyridine. Dihydroxylation of these didehydro derivatives with osmium tetroxide or with AD-mix α gave a mixture of erythrofuranosyl C-nucleosides that were separated by standard and then chiral chromatography. When screened for anti-HCMV and HSV-1 activity, the α-D anomer of 2,6,7-trichloro-3-(erythrofuranosyl)imidazo[1,2-a]pyridine proved to be the most active member of the series, while the α-anomers all proved to be inactive.

Imidazo[1,2-a]pyridine C-nucleosides as antiviral agents

This invention pertains to nucleoside analogs that have antiviral activity and improved metabolic stability, compositions comprising them, and methods of antiviral treatment employing them. More particularly, this invention pertains to imidazo[1,2-a]pyridine C-nucleosides, as exemplified by compounds such as imidazo[l,2-a]pyridine C5-nucleosides and imidazo[1,2-a]pyridine C3-nucleosides, and may be represented by formula (I), wherein exactly one of Q3and Q5is a sugar-like moiety; exactly one of Q3and Q5is —H; and Q2, Q6, Q7and Q8are independently imidazo[1,2-a]pyridine substituents, such as —H, —F, —Cl, —Br and —I.